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Abstract 
 
Background: It can be difficult to engage consumers in health decision making.  This is 
particularly so in the area of palliative care, where consumers are very unwell and are 
unlikely to become involved in long term programs that promote consumer input.  This 
paper explores the possibility of using ‘Consumer Impact Statements’ to facilitate the 
inclusion of the viewpoint of people at the end of life in the process of policy and 
decision making, particularly in the area of subsidy of pharmaceuticals used in 
palliative care.  
 
Search Strategy: A broad search was conducted to find information about the use of 
impact statements in any health field. The health literature and grey literature were 
searched to explore the use of Consumer Impact Statements to date. 
 
Results: No papers were found describing the use of Consumer Impact Statements in 
the palliative care setting. Health impact assessment is used in the areas of 
environmental health and community health. Impact statements are less commonly 
used in other areas of health, especially policy development, and no formal description 
of a Consumer Impact Statement was found.  
 
Discussion: There is considerable scope for developing the use of Consumer Impact 
Statements to promote the consumer viewpoint in health decision making, because it 
will allow people who are otherwise unlikely to contribute to the public debate to have 
their views heard by decision makers.  
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 Conclusion: The use of Consumer Impact Statements is particularly suited to palliative 
care, given that consumers are often otherwise unable to contribute to the public 
debate.  
 
Keywords: consumer participation; impact statements; palliative care, end of life care; 
pharmaceutical subsidy 
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Promoting the consumer voice in palliative care: exploring the possibility of using 
consumer impact statements 
Background  
Consumer involvement in health policy is highly valued by governments and policy 
makers1, however, there is little empirical evidence about the best way to engage 
consumers and elicit a consumer perspective2-3. Further study is required to determine 
which methods of engaging consumers are successful in allowing them to have a voice 
in making public policy4. 
 
In the hospice/palliative care setting, engaging consumers offers considerable 
challenges. Palliative care patients are, by definition, seriously ill and may be too frail 
to participate in activities that promote consumer input. However, it is important that 
the experiences of this group of people be heard to ensure that hospice/palliative care 
is appropriately funded and that policy frameworks serve consumer needs. Despite a 
growing interest in making hospice/palliative care services more patient focused and 
consumer driven, there remains little direction on how this can be achieved 
systematically5. As such, it is incumbent on the palliative care community to attempt to 
develop ways of engaging hospice/palliative care patients in the on-going dialogue 
about end of life care that allow for seriously ill people to contribute.  
 
In Australia, the federal Government has subsidised medications since 19446, but there 
have been limitations associated with the inclusion of medications required in 
palliative care.  Medicines undergo a rigorous assessment process prior to being 
approved for inclusion in the pharmaceutical benefits scheme, which includes an initial 
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assessment of safety and efficacy by the Therapeutic Goods Administration followed 
by comparative cost effectiveness. This requires a strong evidence base and there has 
been no incentive for industry to support developing the evidence base just for 
indications for use in palliative care given that the market for palliative medications is 
relatively small and time limited, and most medications where additional evidence is 
needed are already beyond their period of patent.  Therefore, the purpose of this 
paper is to examine ways that the literature describes consumers’ (people requiring 
palliative care and their carers) contribution to decision making and influencing policy 
relating to subsidy of pharmaceutical agents used to ameliorate symptoms at the end 
of life. In particular, the paper aims to explore the potential use of consumer impact 
statements to assist with medication assessment in the palliative care context. 
 
Search strategy 
An extensive search of the literature in the areas of health and medicine was 
undertaken, for papers published between 2000-2012, that describe or discuss the use 
of consumer impact statements in the health care setting.  The search was conducted 
using the health related databases Medline, CINAHL, EMBASE, International 
Pharmaceutical Abstracts, DRUG, Proquest and Current Contents.   The search terms 
used are included in Table 1. Two key journals, Australian Health Review and Health 
Expectations, were identified and hand searched.   
 
The grey literature was also searched.  Caresearch7, an Australian palliative care 
website that includes a large anthology of palliative care related grey literature, was 
used as a starting point. Then, the websites of all health departments in Australia, New 
 5 
Archived at Flinders University: dspace.flinders.edu.au
Zealand, Canada, the United Kingdom and the United States of America were 
searched.  Evidence-based practice organisations, including the Cochrane Collection, 
Joanna Briggs Institute and the National Institute of Clinical Excellence (NICE) were also 
searched. To ensure that no data were overlooked, an email was sent to each of these 
departments explaining the purpose of this project and requesting any relevant 
information.  Data from consumer advocacy groups in each country were also sought, 
relevant websites were searched and requests for information sent.  Open SIGLE, a 
database of grey literature from Europe, was used to search European literature 
available in English translation.  Internet sites relating to experiences of chronic illness 
were also searched, with a focus on blogs and on-line fora that describe consumers’ 
experiences.   
 
Results 
The literature search revealed almost no information about the use of impact 
statements in any area of health, and no information was found that related directly to 
the use of these statements in the area of palliative care or pharmaceutical decision 
making.  Papers were considered relevant if they considered issues of consumer 
participation in pharmaceutical policy development; consumer input into any aspect of 
palliative care or the use of impact assessment in policy development. The search of 
the health-related databases resulted in a small number of articles that were relevant, 
albeit indirectly, to the issue of Consumer Impact Statement use in a palliative care 
medications context. As such, this paper presents an overview of related issues and 
discusses the potential of using impact statements to increase the palliative care 
consumer voice in pharmaceutical decision making.  
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Health Impact Assessments 
A health impact assessment uses a variety of methods to determine what impact 
health projects or policies will have on the population most likely to be affected8. The 
World Health Organisation9 states that: 
 
…health impact assessment is a practical approach used to judge the potential health 
effects of a policy, program or project on a population, particularly on vulnerable or 
disadvantaged groups. 
 
Health impact assessments are widely used in the environmental health area, but can 
be used to guide any project that may have an impact on the health of a group of 
people, and are appropriate in areas as diverse as health promotion, environmental 
health and public health10. The main points considered in health impact assessments 
are the relationship between the project or policy and the health of a population; input 
of the population that is likely to be affected by the illness (without the ability of 
service providers or vendors to influence statements); expert opinion and options to 
minimise health risks and maximise positive health outcomes11. 
Health impact assessments have five key parts:   
i. Screening to assess the need for a health impact assessment;  
ii. scoping to determine what is included in the assessment; 
iii. assessing health impacts by identifying and analysing potential effects; 
iv. decision making, prioritising the issues and developing recommendations; and 
v. evaluation of the health impact assessment itself, and potentially of the health 
impacts described as well.10,12 
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 In relation to pharmaceutical products, the key need is for decision makers to 
understand the impact a disease or condition has on the lives of patients and their 
caregivers. Governments from a number of countries have developed guidelines for 
health impact assessments.  The Australian Government developed Health Impact 
Assessment Guidelines primarily for use as part of a wider environmental health 
impact assessment13.  Similar guidelines are also available in New Zealand14, England15  
and Wales16.  The guidelines require a health impact assessment to be conducted 
when developing policies, programs or projects that may impact on the health of a 
population, however, they are largely focused on environmental health projects such 
as building or industrial development.  
 
In the public health sphere, health impact statements are used routinely when a 
project is likely to have an effect on a vulnerable population. The Equity-Focused 
Health Impact Assessment Framework17 assists with conducting impact assessments on 
proposals that are likely to affect minority sectors of the Australian community that 
may otherwise not be considered. The Antigonish (Canada) Community Health Impact 
Assessment Tool18 uses a comprehensive checklist to examine the impact of any health 
related project on the community, and examines a broad range of issues including 
child health, environmental health, community demographics, income and social 
status, social environment and networks, and personal health and health services. 
There is less information about how health impact assessment can be used in other 
sectors of health, including development of public policy12.  
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Consumer Impact Statements 
While health impact assessment is well established in some areas, there is less 
information about the development of impact statements that describe the effect of a 
policy or decision on health care consumers, or the implications for patients of a 
specific condition, disease, or symptom especially in relation to the subsidisation of 
relevant pharmaceuticals.  
 
In Australia an Aboriginal Health Impact Statement19-20 is required to accompany 
proposals for health policies, programs and strategies that will have a significant effect 
on Aboriginal peoples. The impact statement is accompanied by a checklist that details 
how consultation was undertaken and how the needs of this consumer group have 
been met.  This method of impact statement development could form the basis of 
ensuring that other under-represented groups have a say in public policy setting.  
 
Impact statements that describe the impact of a disease or symptom are not common 
and only one was found in this search. The Joint Epilepsy Council of Australia prepared 
an impact statement that involved extensive consultation with people with epilepsy 
(n=467) and carergivers of people with epilepsy (n=496)21. The four page report covers 
a range of topics relating to life with epilepsy, including information about diagnosis, 
treatment, and the impact of epilepsy on everyday life, worklife and psychosocial 
issues, and demonstrates the effectiveness of using a concise impact statement to 
illustrate the effects of living with a disease.  A similar format could be used to describe 
other diseases or troublesome symptoms. No information is available about the most 
appropriate process for developing a disease-specific impact statement. 
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 Impact Statements in Palliative Care 
We have been unable to find any evidence that impact statements are in use in the 
hospice/palliative care setting. Despite this, there are a number of reasons to consider 
impact statements as an option for increasing the input of seriously ill people into 
policy decisions. In particular, the lack of a consumer voice in this area suggests the 
need for other ways of compiling and presenting information about the experiences of 
seriously ill people and their caregivers. An impact statement may consider data from 
a number of sources, including research and other professional literature, personal 
accounts and data collected by survey, interview or other means. A considerable 
advantage of developing structured impact statements relating to palliative care is that 
data collection could be brief in order to minimise patients’ and families’ burden.   
 
The perceived vulnerability of the palliative care patient group means that there are 
specific issues to be considered if health impact statements are used as a means of 
promoting consumer input in hospice/palliative care policy making and practice. While 
impact statements have the potential to provide a voice to a largely unheard group, 
the collection of data for the impact statements needs to be considered in terms of 
ethical issues. The timing of data collection is crucial if the true impact of a symptom 
experienced by a seriously ill person is being measured, however there are obvious 
limitations to collecting data in the terminal phase of illness. Therefore, it should be 
noted that it is unlikely that any impact statement can reflect accurately the entire 
experiences of someone very close to death.  
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Palliative care considers the patient and their family as the ‘unit of care’22. When 
considering the impact of a condition, disease or symptom it is appropriate to consider 
the effect on the family and/or caregiver as well. Including the caregivers’ perspectives 
in a consumer impact statement relating to end of life experiences is of benefit for at 
least two reasons.  Firstly, caregivers and close family members may be able to act as a 
proxy for some key parameters, providing accurate information about the patient’s 
experience23-24. Secondly, the implications of the phenomena being examined on the 
caregiver and close family is of relevance in this setting, both for their willingness to 
continue care for this person and the willingness to potentially provide care in the 
same circumstances again.25 
The development of impact statements that relate to the use of medicines in the 
hospice /palliative care setting offers a unique opportunity to include a consumer 
voice in the medication subsidy debate that may otherwise not be heard. Much of the 
information provided about the need for government subsidy of medications is 
provided by pharmaceutical companies with a vested interest in having a product 
under patent made more readily available for consumers.  Completing an impact 
statement that is demonstrably independent of pharmaceutical company interests 
ensures patients and families have the chance to describe their experiences, the 
impact of this illness and its symptoms on each of them and highlight issues that are of 
importance to them. When completed by an independent body, an impact statement 
is a patient-centred statement of experience and can subsequently help inform 
decision makers about the potential impact of an illness on individuals and their 
families.  
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Gathering Evidence for an Impact Statement 
There is little information about how best to gather data to inform a health impact 
statement. While it is likely that the tenets underpinning health impact assessments 
are suitable for use in the development of consumer impact statements as well, there 
is a need to consider specific methodologies suitable for collecting information from 
seriously ill patients.  The health literature has a large amount of information about 
the experiences of patients and their families using different methods and presented 
in different ways. Each is likely to have some utility in terms of gathering data that are 
useful for inclusion in an impact statement.     
 
There are lots of quantitative studies that describe conditions or symptoms suffered by 
people with specific diseases and a plethora of instruments designed to measure 
symptoms and the impact of symptoms on patients.  These are useful for preparing an 
impact statement as they can offer a range of methods and samples on which to base 
the impact statement. In addition, they may offer insights into the effects of the 
condition on the activities of daily living, physical and psychosocial wellbeing or quality 
of life. For example, a study of symptoms experienced by people with dementia used 
both patient and caregiver reports of symptoms, using a range of instruments 
including the Edmonton Symptom Assessment Scale and the End of Life Dementia 
Scale – Symptom Management26. The study showed that the most commonly reported 
symptoms by patients were pain (42%) and depression (11%) and that caregivers 
reported cognitive deficit as being most prevalent (47%).  Activity disturbance was 
reported by 15% of caregivers.  
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Describing the experience of an illness using qualitative research methods such as 
phenomenology, grounded theory or case study methods is common. Phenomenology 
in particular may be of benefit when preparing an impact statement because it 
examines the lived experience of the phenomena in question, generally using one-to-
one interviews as the method of data collection27.  Examples of phenomenological 
studies of the impact of a disease include Ek and Ternestedt’s28 study of people with 
end-stage chronic obstructive pulmonary disease (COPD) (n=8).  The findings of the 
study described living with COPD as being a life dominated by a lack of physical 
strength that led to a reduction in activities and in turn social isolation because of the 
inability to participate in social activities.  Participants described emotional distress 
and feelings of meaningless that accompanied physical limitations.  Donovan and 
Flynn’s study of the experiences of men with breast cancer (n=15) also used a 
phenomenological approach, using interviews and email conversations to collect 
data29.  The findings of this study described the emotional difficulties men experienced 
suffering what they considered a ‘woman’s disease’ and the effect that this had on 
their personal relationships and sexuality.  The findings of these two studies highlight 
the strength of using a qualitative method to gather data about living with a specific 
condition.  However, sample sizes are small and sampling techniques are purposive, 
potentially limiting generalizability of findings.  
 
Systematic and other reviews of literature are useful for preparing impact statements, 
in that much of the hard work finding appropriate sources of information has already 
been done. Review papers are able to provide a much deeper insight into the 
experiences of people with a specific condition, but do not offer the personal insights 
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found in qualitative research papers.  Embrey’s review of the literature describing the 
experiences of people with multiple sclerosis who require palliative care is an example 
of the efficacy of a literature review in describing disease/symptom impact30.  This 
paper describes the nature of multiple sclerosis, the nature of palliative care for people 
with multiple sclerosis and evaluates palliative care services provided for this group of 
people.   
 
The Internet is also a rich source of patient-centred literature and has a large number 
of sites that relate to the experiences of people with illnesses but there is a question as 
to how representative such fora are.  The most useful of these for preparing impact 
statements are blogs and forums, where people post entries about their own 
experiences.  The quality of these is variable and it is difficult to locate specific 
information when required.  However, an excerpt from a blog about life with 
Parkinson’s Disease demonstrates that the Internet could be a useful source of 
information in this area especially with emerging context monitors for trends and 
patterns of interaction:  
You think you don't entertain me anymore because I'm not grinning or laughing. If I 
appear to stare at you, or have a wooden expression, that's the Parkinson's, I hear you. 
I have the same intelligence; it just isn't easy to show facial expressions. If swallowing, I 
may drool. This bothers me, so I will mop it up….. 
(http://katekelsall.typepad.com/my_weblog/). 
Statements such as these could form a useful adjunct to an impact statement and 
could be used to gather qualitative data about a disease or symptom.  However, the 
 14 
Archived at Flinders University: dspace.flinders.edu.au
nature of the Internet makes it difficult to verify the accuracy and completeness of 
these accounts and searching can be cumbersome and slow. 
 
The Role of Consumer Impact Statements in Pharmaceutical Policy Development  
Preparation of Consumer Impact Statements is likely to be led by the palliative care research 
community aiming to build a body of evidence to support the need for greater access to 
medications for people requiring palliative care. The data required for completing a consumer 
impact statement needs to be collected from a range of sources using a range of methods, so 
that a comprehensive and balanced account of the impact on patients and their caregivers of 
a condition, disease or symptom is compiled.  As yet, there are few data about the 
appropriateness of specific methodologies that are suitable for use in this population and it is 
important that methods used do not prove burdensome to patients and families. The next 
logical step is to determine ways in which data can be collected to develop impact statements 
that are suitable for patients and families close to the end of life and that will result in high 
quality, useful data being available to inform healthcare decision making. 
Conclusion  
Health impact assessment is becoming more widely accepted as a method of assessing 
the impact of a government policy, but as yet there is  no precedent for using an 
impact statement in the palliative care setting or pharmaceutical subsidy decision 
making process. However, it is reasonable to expect that consumers will get a say in 
the decision that is made and will be able to inform decision makers of their 
experiences and needs. In the palliative care setting, where people are often seriously 
ill and perceived to be vulnerable, participating in research is justified if it will benefit 
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the participants and others and, as such, being a part of developing an impact 
statement is an appropriate way for people at the end of life to contribute to health 
care decision making.  
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Table 1: Search terms for literature review 
Mesh Heading Alternative Terms 
Consumer participation Consumer involvement 
Patient participation 
Patient involvement 
Public participation 
Public involvement 
Engaging consumers 
Engaging patients 
Engaging public 
Consumer advocacy 
Patient advocacy 
Drug approval New drug approval 
Drug approval process 
Drug policy 
Pharmaceutical policy 
 Health impact statement/health statement 
Consumer impact statement/consumer 
statement 
Symptom impact statement 
Disease impact statement 
 Lived experience /symptom/disease 
Living with/symptom disease 
Describing symptom/disease 
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Carer/caregiver/lived experience 
 Patient story 
Patient anecdote 
Patient experience 
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